A RADIOPHARMACEUTICAL FOR IMAGING AREAS OF LYMPHOCYTIC INFILTRATION - I-125 INTERLEUKIN-2 - LABELING PROCEDURE AND ANIMAL STUDIES

被引:67
作者
SIGNORE, A
CHIANELLI, M
TOSCANO, A
MONETINI, L
RONGA, G
NIMMON, CC
BRITTON, KE
POZZILLI, P
NEGRI, M
机构
[1] Cattedra di Fisiopatologia Applicata, Istituto Clinica Medica II, Policlinico Umberto I, Roma
[2] Department of Nuclear Medicine, St Bartholomew's Hospital
关键词
D O I
10.1097/00006231-199213100-00003
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The labelling of interleukin-2 (IL-2) with I-123 and its in vivo application for imaging chronic pathological lymphocytic infiltrations are described. The lactoperoxidase/glucoseoxidase technique was the labelling method of choice leading to immunoreactive IL-2 with high specific activity. Labelled IL-2 was injected in diabetes-prone non-obese diabetic (NOD) mice with pancreatic lymphocytic infiltration. As control animals, Balb/c mice were used. As specificity control, monoclonal antibodies AMT13 and UCHT1, bovine serum albumin and alpha-lactalbumin were radioiodinated and injected in mice. Eighteen NOD mice and four control Balb/c mice were used for gamma camera imaging experiments. Fifty-four NOD and 20 Balb/c mice were used for time course single organ counting and autoradiography. Gamma camera images showed that radioactivity accumulated in the pancreatic region from the 10th minute onwards in NOD mice injected with I-123-IL-2 but not in Balb/c mice, or in NOD mice injected with control radiopharmaceuticals. These findings were confirmed by counting the radioactivity present in single organs. Autoradiography of NOD pancreas, after injection of labelled IL-2, showed that radioactivity was specifically associated with infiltrating lymphocytes. In conclusion, this technique is highly specific and easy to perform and we suggest its application in humans for in vivo detection of areas of lymphocytic infiltration.
引用
收藏
页码:713 / 722
页数:10
相关论文
共 39 条
[21]  
Morgan D.A., Ruscetti F., Gallo R., Selective in vitro growth factor of T lymphocytes from normal human bone marrow, Science, 193, pp. 1007-1009, (1976)
[22]  
Robb R.J., Munck A., Smith K.A., T-cell growth factor receptors: Quantitation, specificity and biological relevance, J Exp Med, 154, pp. 1455-1474, (1981)
[23]  
Donohue J.H., Rosenberg S.A., The fate of interleukin-2 after in vivo administration, J Immunol, 130, pp. 2203-2208, (1983)
[24]  
Koths K., Halenbeck R., Pharmakokinetic studies on 35S- labelled recombinant interleukin-2 in mice, Cellular and Molecular Biology of Lymphokines, pp. 779-783, (1985)
[25]  
Muhlradt P.F., Opit H.C., Clearance of interleukin 2 from the blood of normal and T cell-depleted mice, Eur J Immunol, 12, pp. 983-985, (1982)
[26]  
Lampeter E.F., Signore A., Gale E.A., Et al., Lessons from the NOD mouse for the pathogenesis and immunotherapy of human type 1 (Insulin-dependent) diabetes mellitus, Diabetologia, 32, pp. 703-708, (1989)
[27]  
Signore A., Pozzilli P., Gale E., Et al., The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice, Diabetologia, 32, pp. 282-289, (1989)
[28]  
Signore A., Cooke A., Pozzilli P., Et al., Class-II and IL2 receptor positive cells in the pancreas of NOD mice, Diabetologia, 30, pp. 902-905, (1987)
[29]  
Hodgkinson S.C., Landon J., Lowry P.J., A liquid-phase two- site immunoradiometric assay for human prolactin, Biochem J, 217, pp. 273-279, (1984)
[30]  
Osawa H., Diamantstein T., A rat monoclonal antibody that binds specifically to mouse T lymphoblasts and inhibits IL receptor functions: A putative anti-IL 2 receptor antibody, J Immunol, 132, pp. 2445-2450, (1984)